Clinical trials

Condition   Drug Name  
Study 12B75 in psoriasis
Design Randomized
Treatment Regimen 12B75, 45 mg; 12B75, 90 mg; Placebo
Conclusions 12B75 reduced epidermal thickness by >50% and markers of cellular proliferation and T-cell infiltration by up to 80% in patients with psoriasis
Reference(s) Immunohistochemical changes in lesional tissue and impact on systemic immune markers following CNTO 1275 treatment in patients with psoriasis
J Invest Dermatol 2007, 127 (Suppl. 1):Abst 719.
Author and Affiliation Reddy, M., Torres, G., McCormick, T., Marano, C., Cooper, K., Yeilding, N., Hsu, M., Pendley, C., Prabhakar, U., et al.